1
|
Liu L, Johnson PD, Prime ME, Khetarpal V, Lee MR, Brown CJ, Chen X, Clark-Frew D, Coe S, Conlon M, Davis R, Ensor S, Esposito S, Moren AF, Gai X, Green S, Greenaway C, Haber J, Halldin C, Hayes S, Herbst T, Herrmann F, Heßmann M, Hsai MM, Kotey A, Mangette JE, Mills MR, Monteagudo E, Nag S, Nibbio M, Orsatti L, Schaertl S, Scheich C, Sproston J, Stepanov V, Varnäs K, Varrone A, Wityak J, Mrzljak L, Munoz-Sanjuan I, Bard JA, Dominguez C. [ 11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins. J Med Chem 2021; 64:12003-12021. [PMID: 34351166 DOI: 10.1021/acs.jmedchem.1c00667] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The expanded polyglutamine-containing mutant huntingtin (mHTT) protein is implicated in neuronal degeneration of medium spiny neurons in Huntington's disease (HD) for which multiple therapeutic approaches are currently being evaluated to eliminate or reduce mHTT. Development of effective and orthogonal biomarkers will ensure accurate assessment of the safety and efficacy of pharmacologic interventions. We have identified and optimized a class of ligands that bind to oligomerized/aggregated mHTT, which is a hallmark in the HD postmortem brain. These ligands are potentially useful imaging biomarkers for HD therapeutic development in both preclinical and clinical settings. We describe here the optimization of the benzo[4,5]imidazo[1,2-a]pyrimidine series that show selective binding to mHTT aggregates over Aβ- and/or tau-aggregates associated with Alzheimer's disease pathology. Compound [11C]-2 was selected as a clinical candidate based on its high free fraction in the brain, specific binding in the HD mouse model, and rapid brain uptake/washout in nonhuman primate positron emission tomography imaging studies.
Collapse
Affiliation(s)
- Longbin Liu
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Peter D Johnson
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Michael E Prime
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Vinod Khetarpal
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Matthew R Lee
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Christopher J Brown
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Xuemei Chen
- Albany Molecular Research, Inc., 1001 Main Street, Buffalo, New York 14203, United States
| | - Daniel Clark-Frew
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Samuel Coe
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Mike Conlon
- Albany Molecular Research, Inc., 1001 Main Street, Buffalo, New York 14203, United States
| | - Randall Davis
- Albany Molecular Research, Inc., 1001 Main Street, Buffalo, New York 14203, United States
| | - Samantha Ensor
- Albany Molecular Research, Inc., 1001 Main Street, Buffalo, New York 14203, United States
| | - Simone Esposito
- IRBM, IRBM Science Park S.p.A., Via Pontina Km 30,600, Pomezia, Rome 00071, Italy
| | - Anton Forsberg Moren
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, Stockholm S-17176, Sweden
| | - Xinjie Gai
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Samantha Green
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Catherine Greenaway
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - James Haber
- Albany Molecular Research, Inc., 1001 Main Street, Buffalo, New York 14203, United States
| | - Christer Halldin
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, Stockholm S-17176, Sweden
| | - Sarah Hayes
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Todd Herbst
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Frank Herrmann
- Evotec SE, Manfred Eigen Campus, Essener Bogen 7, Hamburg 22419, Germany
| | - Manuela Heßmann
- Evotec SE, Manfred Eigen Campus, Essener Bogen 7, Hamburg 22419, Germany
| | - Ming Min Hsai
- Albany Molecular Research, Inc., 1001 Main Street, Buffalo, New York 14203, United States
| | - Adrian Kotey
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - John E Mangette
- Albany Molecular Research, Inc., 1001 Main Street, Buffalo, New York 14203, United States
| | - Matthew R Mills
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Edith Monteagudo
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Sangram Nag
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, Stockholm S-17176, Sweden
| | - Martina Nibbio
- IRBM, IRBM Science Park S.p.A., Via Pontina Km 30,600, Pomezia, Rome 00071, Italy
| | - Laura Orsatti
- IRBM, IRBM Science Park S.p.A., Via Pontina Km 30,600, Pomezia, Rome 00071, Italy
| | - Sabine Schaertl
- Evotec SE, Manfred Eigen Campus, Essener Bogen 7, Hamburg 22419, Germany
| | - Christoph Scheich
- Evotec SE, Manfred Eigen Campus, Essener Bogen 7, Hamburg 22419, Germany
| | - Joanne Sproston
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Vladimir Stepanov
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, Stockholm S-17176, Sweden
| | - Katarina Varnäs
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, Stockholm S-17176, Sweden
| | - Andrea Varrone
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, Stockholm S-17176, Sweden
| | - John Wityak
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Ladislav Mrzljak
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Ignacio Munoz-Sanjuan
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Jonathan A Bard
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Celia Dominguez
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| |
Collapse
|
2
|
Liu L, Prime ME, Lee MR, Khetarpal V, Brown CJ, Johnson PD, Miranda-Azpiazu P, Chen X, Clark-Frew D, Coe S, Davis R, Dickie A, Ebneth A, Esposito S, Gadouleau E, Gai X, Galan S, Green S, Greenaway C, Giles P, Halldin C, Hayes S, Herbst T, Herrmann F, Heßmann M, Jia Z, Kiselyov A, Kotey A, Krulle T, Mangette JE, Marston RW, Menta S, Mills MR, Monteagudo E, Nag S, Nibbio M, Orsatti L, Schaertl S, Scheich C, Sproston J, Stepanov V, Svedberg M, Takano A, Taylor M, Thomas W, Toth M, Vaidya D, Vanräs K, Weddell D, Wigginton I, Wityak J, Mrzljak L, Munoz-Sanjuan I, Bard JA, Dominguez C. Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand. J Med Chem 2020; 63:8608-8633. [PMID: 32662649 DOI: 10.1021/acs.jmedchem.0c00955] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Mutant huntingtin (mHTT) protein carrying the elongated N-terminal polyglutamine (polyQ) tract misfolds and forms protein aggregates characteristic of Huntington's disease (HD) pathology. A high-affinity ligand specific for mHTT aggregates could serve as a positron emission tomography (PET) imaging biomarker for HD therapeutic development and disease progression. To identify such compounds with binding affinity for polyQ aggregates, we embarked on systematic structural activity studies; lead optimization of aggregate-binding affinity, unbound fractions in brain, permeability, and low efflux culminated in the discovery of compound 1, which exhibited target engagement in autoradiography (ARG) studies in brain slices from HD mouse models and postmortem human HD samples. PET imaging studies with 11C-labeled 1 in both HD mice and WT nonhuman primates (NHPs) demonstrated that the right-hand-side labeled ligand [11C]-1R (CHDI-180R) is a suitable PET tracer for imaging of mHTT aggregates. [11C]-1R is now being advanced to human trials as a first-in-class HD PET radiotracer.
Collapse
Affiliation(s)
- Longbin Liu
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Michael E Prime
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Matt R Lee
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Vinod Khetarpal
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Christopher J Brown
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Peter D Johnson
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Patricia Miranda-Azpiazu
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Xuemei Chen
- Albany Molecular Research, Inc., 1001 Main St., Buffalo, New York 14203, United States
| | - Daniel Clark-Frew
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Samuel Coe
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Randall Davis
- Albany Molecular Research, Inc., 1001 Main St., Buffalo, New York 14203, United States
| | - Anthony Dickie
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Andreas Ebneth
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Simone Esposito
- IRBM, IRBM Science Park S.p.A., Via Pontina Km 30, 600, 00071 Pomezia (RM), Italy
| | - Elise Gadouleau
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Xinjie Gai
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Sebastien Galan
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Samantha Green
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Catherine Greenaway
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Paul Giles
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Christer Halldin
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Sarah Hayes
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Todd Herbst
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Frank Herrmann
- Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Manuela Heßmann
- Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Zhisheng Jia
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Alexander Kiselyov
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Adrian Kotey
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Thomas Krulle
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - John E Mangette
- Albany Molecular Research, Inc., 1001 Main St., Buffalo, New York 14203, United States
| | - Richard W Marston
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Sergio Menta
- IRBM, IRBM Science Park S.p.A., Via Pontina Km 30, 600, 00071 Pomezia (RM), Italy
| | - Matthew R Mills
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Edith Monteagudo
- IRBM, IRBM Science Park S.p.A., Via Pontina Km 30, 600, 00071 Pomezia (RM), Italy
| | - Sangram Nag
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Martina Nibbio
- IRBM, IRBM Science Park S.p.A., Via Pontina Km 30, 600, 00071 Pomezia (RM), Italy
| | - Laura Orsatti
- IRBM, IRBM Science Park S.p.A., Via Pontina Km 30, 600, 00071 Pomezia (RM), Italy
| | - Sabine Schaertl
- Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Christoph Scheich
- Evotec AG, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany
| | - Joanne Sproston
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Vladimir Stepanov
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Marie Svedberg
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Akihiro Takano
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Malcolm Taylor
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Wayne Thomas
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Miklós Toth
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Darshan Vaidya
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Katarina Vanräs
- Department of Clinical Neuroscience, Centre for Psychiatric Research, Karolinska Hospital, Karolinska Institutet, S-17176 Stockholm, Sweden
| | - Derek Weddell
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - Ian Wigginton
- Evotec (U.K.) Ltd, 114 Innovation Drive, Milton Park, Abingdon OX14 4RZ, U.K
| | - John Wityak
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Ladislav Mrzljak
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Ignacio Munoz-Sanjuan
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Jonathan A Bard
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| | - Celia Dominguez
- CHDI Management/CHDI Foundation, 6080 Center Drive, Suite 700, Los Angeles, California 90045, United States
| |
Collapse
|
3
|
Nune KC, Misra RDK, Gai X, Li SJ, Hao YL. Surface nanotopography-induced favorable modulation of bioactivity and osteoconductive potential of anodized 3D printed Ti-6Al-4V alloy mesh structure. J Biomater Appl 2017; 32:1032-1048. [DOI: 10.1177/0885328217748860] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
The objective of the study described here is to fundamentally elucidate the biological response of 3D printed Ti-6Al-4V alloy mesh structures that were surface modified to introduce titania nanotubes with an average pore size of ∼80 nm via an electrochemical anodization process from the perspective of enhancing bioactivity. The bioactivity of the mesh structures were analyzed through immersion test in simulated body fluid, which confirmed the nucleation and growth of fine globular nanoscale apatite on the nanoporous titania-modified (anodized) mesh structure surface, and agglomerated apatite with fine flakes of apatite crystals on as-fabricated mesh structure surface, that were rich in calcium and phosphorous. The cellular activity of bioactive anodized mesh structure was explored in terms of cell–material interactions involving adhesion, proliferation, synthesis of extracellular and intracellular proteins, differentiation, and mineralization. Cells adhered with a sheet-like morphology on as-fabricated mesh structure, whereas, on anodized mesh structure, numerous filopodia-like cellular extensions interacting with nanotube pores were observed. The formation of a bioactive nanoscale apatite, cell–nanotube interactions as imaged via electron microscopy, higher expression of proteins (actin, vinculin, fibronectin, and alkaline phosphatase (ALP)), and calcium content points toward the determining role of anodized mesh structure in modulating osteoblasts functions. The unique combination of nanoporous bioactive titania and interconnected porous architecture of anodized titanium alloy mesh structure provided a multimodal roughness surface ranging from nano to micro to macroscale, which helps in attaining strong primary and secondary fixation of the implant device along with the pathway for supply of nutrients and oxygen to cells and tissue.
Collapse
Affiliation(s)
- KC Nune
- Department of Metallurgical, Materials and Biomedical Engineering, University of Texas at El Paso, El Paso, TX, USA
| | - RDK Misra
- Department of Metallurgical, Materials and Biomedical Engineering, University of Texas at El Paso, El Paso, TX, USA
| | - X Gai
- Shenyang National Laboratory for Materials Science, Institute of Metals Research, Chinese Academy of Sciences, Shenyang, China
| | - SJ Li
- Shenyang National Laboratory for Materials Science, Institute of Metals Research, Chinese Academy of Sciences, Shenyang, China
| | - YL Hao
- Shenyang National Laboratory for Materials Science, Institute of Metals Research, Chinese Academy of Sciences, Shenyang, China
| |
Collapse
|
4
|
Gai X, Xie HM, Perin JC, Takahashi N, Murphy K, Wenocur AS, D'arcy M, O'Hara RJ, Goldmuntz E, Grice DE, Shaikh TH, Hakonarson H, Buxbaum JD, Elia J, White PS. Rare structural variation of synapse and neurotransmission genes in autism. Mol Psychiatry 2012; 17:402-11. [PMID: 21358714 PMCID: PMC3314176 DOI: 10.1038/mp.2011.10] [Citation(s) in RCA: 123] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Autism spectrum disorders (ASDs) comprise a constellation of highly heritable neuropsychiatric disorders. Genome-wide studies of autistic individuals have implicated numerous minor risk alleles but few common variants, suggesting a complex genetic model with many contributing loci. To assess commonality of biological function among rare risk alleles, we compared functional knowledge of genes overlapping inherited structural variants in idiopathic ASD subjects relative to healthy controls. In this study we show that biological processes associated with synapse function and neurotransmission are significantly enriched, with replication, in ASD subjects versus controls. Analysis of phenotypes observed for mouse models of copy-variant genes established significant and replicated enrichment of observable phenotypes consistent with ASD behaviors. Most functional terms retained significance after excluding previously reported ASD loci. These results implicate several new variants that involve synaptic function and glutamatergic signaling processes as important contributors of ASD pathophysiology and suggest a sizable pool of additional potential ASD risk loci.
Collapse
Affiliation(s)
- X Gai
- Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - H M Xie
- Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - J C Perin
- Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - N Takahashi
- Seaver Autism Center and Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
| | - K Murphy
- Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - A S Wenocur
- Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - M D'arcy
- Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - R J O'Hara
- Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - E Goldmuntz
- Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA,Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | - D E Grice
- Department of Child and Adolescent Psychiatry, Columbia University, New York, NY, USA
| | - T H Shaikh
- Department of Pediatrics, University of Colorado School of Medicine, Denver, CO, USA
| | - H Hakonarson
- Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA,Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, USA,Division of Pulmonary Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - J D Buxbaum
- Seaver Autism Center and Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
| | - J Elia
- Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia, Philadelphia, PA, USA,Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | - P S White
- Center for Biomedical Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA,Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA,Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA,Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Room 1407 CHOP North, Philadelphia, PA 19104-4318, USA. E-mail:
| |
Collapse
|
5
|
Gai X, Wang RP, Xiong C, Steel MJ, Eggleton BJ, Luther-Davies B. Near-zero anomalous dispersion Ge11.5As24Se64.5 glass nanowires for correlated photon pair generation: design and analysis. Opt Express 2012; 20:776-786. [PMID: 22274423 DOI: 10.1364/oe.20.000776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We show that highly nonlinear chalcogenide glass nanowire waveguides with near-zero anomalous dispersion should be capable of generating correlated photon-pairs by spontaneous four-wave mixing at frequencies detuned by over 17 THz from the pump where Raman noise is absent. In this region we predict a photon pair correlation of >100, a figure of merit >10 and brightness of ~8×10(8) pairs/s over a bandwidth of >15 THz in nanowires with group velocity dispersion of <5 ps∙km(-1) nm(-1). We present designs for double-clad Ge(11.5)As(24)Se(64.5) glass nanowires with realistic tolerance to fabrication errors that achieve near-zero anomalous dispersion at a 1420 nm pump wavelength. This structure has a fabrication tolerance of 80-170 nm in the waveguide width and utilizes a SiO(2)/Al(2)O(3) layer deposited by atomic layer deposition to compensate the fabrication errors in the film thickness.
Collapse
Affiliation(s)
- X Gai
- Centre for Ultrahigh-bandwidth Devices for Optical Systems (CUDOS), Research School of Physics and Engineering, The Australian National University, Canberra ACT, Australia.
| | | | | | | | | | | |
Collapse
|
6
|
Lind C, Ferriola D, Mackiewicz K, Heron S, Rogers M, Slavich L, Walker R, Hsiao T, McLaughlin L, D'Arcy M, Gai X, Goodridge D, Sayer D, Monos D. Next-generation sequencing: the solution for high-resolution, unambiguous human leukocyte antigen typing. Hum Immunol 2010; 71:1033-42. [DOI: 10.1016/j.humimm.2010.06.016] [Citation(s) in RCA: 117] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2010] [Revised: 06/15/2010] [Accepted: 06/22/2010] [Indexed: 11/16/2022]
|
7
|
Elia J, Gai X, Xie HM, Perin JC, Geiger E, Glessner JT, D'arcy M, deBerardinis R, Frackelton E, Kim C, Lantieri F, Muganga BM, Wang L, Takeda T, Rappaport EF, Grant SFA, Berrettini W, Devoto M, Shaikh TH, Hakonarson H, White PS. Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry 2010; 15:637-46. [PMID: 19546859 PMCID: PMC2877197 DOI: 10.1038/mp.2009.57] [Citation(s) in RCA: 414] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common and highly heritable disorder, but specific genetic factors underlying risk remain elusive. To assess the role of structural variation in ADHD, we identified 222 inherited copy number variations (CNVs) within 335 ADHD patients and their parents that were not detected in 2026 unrelated healthy individuals. Although no excess CNVs, either deletions or duplications, were found in the ADHD cohort relative to controls, the inherited rare CNV-associated gene set was significantly enriched for genes reported as candidates in studies of autism, schizophrenia and Tourette syndrome, including A2BP1, AUTS2, CNTNAP2 and IMMP2L. The ADHD CNV gene set was also significantly enriched for genes known to be important for psychological and neurological functions, including learning, behavior, synaptic transmission and central nervous system development. Four independent deletions were located within the protein tyrosine phosphatase gene, PTPRD, recently implicated as a candidate gene for restless legs syndrome, which frequently presents with ADHD. A deletion within the glutamate receptor gene, GRM5, was found in an affected parent and all three affected offspring whose ADHD phenotypes closely resembled those of the GRM5 null mouse. Together, these results suggest that rare inherited structural variations play an important role in ADHD development and indicate a set of putative candidate genes for further study in the etiology of ADHD.
Collapse
Affiliation(s)
- J Elia
- Department of Child and Adolescent Psychiatry, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, PA, USA
| | - X Gai
- Center for Biomedical Informatics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - H M Xie
- Center for Biomedical Informatics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - J C Perin
- Center for Biomedical Informatics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - E Geiger
- Division of Genetics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - J T Glessner
- Center for Applied Genomics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - M D'arcy
- Center for Biomedical Informatics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - R deBerardinis
- Department of Child and Adolescent Psychiatry, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - E Frackelton
- Center for Applied Genomics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - C Kim
- Center for Applied Genomics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - F Lantieri
- Division of Genetics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - B M Muganga
- Center for Biomedical Informatics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - L Wang
- Center for Biomedical Informatics, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - T Takeda
- Department of Child and Adolescent Psychiatry, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - E F Rappaport
- Joseph Stokes Jr Research Institute, The Children's Hospital of Philadelphia Philadelphia, PA, USA
| | - S F A Grant
- Division of Genetics, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Center for Applied Genomics, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Department of Pediatrics, University of Pennsylvania School of Medicine Philadelphia, PA, USA
| | - W Berrettini
- Department of Psychiatry, University of Pennsylvania School of Medicine Philadelphia, PA, USA
| | - M Devoto
- Division of Genetics, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Department of Pediatrics, University of Pennsylvania School of Medicine Philadelphia, PA, USA,Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine Philadelphia, PA, USA,Dipartimento di Medicina Sperimentale, University La Sapienza Rome, Italy
| | - T H Shaikh
- Division of Genetics, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Department of Pediatrics, University of Pennsylvania School of Medicine Philadelphia, PA, USA
| | - H Hakonarson
- Center for Applied Genomics, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Department of Pediatrics, University of Pennsylvania School of Medicine Philadelphia, PA, USA,Division of Pulmonary Medicine, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Author for correspondence:
| | - P S White
- Center for Biomedical Informatics, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Department of Pediatrics, University of Pennsylvania School of Medicine Philadelphia, PA, USA,Division of Oncology, The Children's Hospital of Philadelphia Philadelphia, PA, USA,Author for correspondence:
| |
Collapse
|
8
|
Lind C, Ferriola D, Mackiewicz K, D'Arcy M, Gai X, Goodridge D, Sayer D, Dapprich J, Monos D. 14-W: Sequencing for the genomic characterization of HLA-A, B, C, DRB1 and DQB1 loci. Hum Immunol 2009. [DOI: 10.1016/j.humimm.2009.09.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Wang G, Lei H, Wang X, Das D, Hong J, Mackinnon CH, Coulter TS, Montalbetti CA, Mears R, Gai X, Bailey SE, Ruhrmund D, Hooi L, Misialek S, Rajagopalan PR, Cheng RK, Barker JJ, Felicetti B, Schönfeld DL, Stoycheva A, Buckman BO, Kossen K, Seiwert SD, Beigelman L. HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives. Bioorg Med Chem Lett 2009; 19:4480-3. [DOI: 10.1016/j.bmcl.2009.05.022] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2009] [Revised: 05/05/2009] [Accepted: 05/06/2009] [Indexed: 11/27/2022]
|
10
|
Dondas HA, Fishwick CWG, Gai X, Grigg R, Kilner C, Dumrongchai N, Kongkathip B, Kongkathip N, Polysuk C, Sridharan V. Stereoselective Palladium-Catalyzed Four-Component Cascade Synthesis of Pyrrolidinyl-, Pyrazolidinyl-, and Isoxazolidinyl Isoquinolines. Angew Chem Int Ed Engl 2005; 44:7570-4. [PMID: 16247817 DOI: 10.1002/anie.200502066] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- H Ali Dondas
- Molecular Innovation, Diversity and Automated Synthesis Centre, School of Chemistry, Leeds University, Leeds, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Dondas HA, Fishwick CWG, Gai X, Grigg R, Kilner C, Dumrongchai N, Kongkathip B, Kongkathip N, Polysuk C, Sridharan V. Stereoselective Palladium-Catalyzed Four-Component Cascade Synthesis of Pyrrolidinyl-, Pyrazolidinyl-, and Isoxazolidinyl Isoquinolines. Angew Chem Int Ed Engl 2005. [DOI: 10.1002/ange.200502066] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
12
|
Grigg R, Gai X, Khamnaen T, Rajviroongit S, Sridharan V, Zhang L, Collard S, Keep A. Synthesis of N-substituted isoindolinones via a palladium catalysed three-component carbonylation amination Michael addition cascade. CAN J CHEM 2005. [DOI: 10.1139/v05-111] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We herein describe a novel palladium catalysed three-component cascade process involving carbonylation of an aryl iodide to generate an acyl palladium(II) species that is intercepted by a primary aliphatic or aromatic amine, amide, or sulfonamide followed by intramolecular Michael addition to furnish N-substituted isoindolinones in good yield. Overall, the cascade results in the formation of one CC and two CN bonds, one ring and one stereocentre.Key words: isoindolinone, palladium, cascade, amidation, sulfonamidation.
Collapse
|
13
|
Gai X, Grigg R, Köppen I, Marchbank J, Sridharan V. Synthesis of carbo- and heterocycles via a palladium-catalysed allene insertion–nucleophile incorporation–Michael addition cascade. Tetrahedron Lett 2003. [DOI: 10.1016/j.tetlet.2003.08.034] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
Xie W, Gai X, Zhu Y, Zappulla DC, Sternglanz R, Voytas DF. Targeting of the yeast Ty5 retrotransposon to silent chromatin is mediated by interactions between integrase and Sir4p. Mol Cell Biol 2001; 21:6606-14. [PMID: 11533248 PMCID: PMC99806 DOI: 10.1128/mcb.21.19.6606-6614.2001] [Citation(s) in RCA: 126] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The Ty5 retrotransposons of Saccharomyces cerevisiae integrate preferentially into regions of silent chromatin at the telomeres and silent mating loci (HMR and HML). We define a Ty5-encoded targeting domain that spans 6 amino acid residues near the C terminus of integrase (LXSSXP). The targeting domain establishes silent chromatin when it is tethered to a weakened HMR-E silencer, and it disrupts telomeric silencing when it is overexpressed. As determined by both yeast two-hybrid and in vitro binding assays, the targeting domain interacts with the C terminus of Sir4p, a structural component of silent chromatin. This interaction is abrogated by mutations in the targeting domain that disrupt integration into silent chromatin, suggesting that recognition of Sir4p by the targeting domain is the primary determinant in Ty5 target specificity.
Collapse
Affiliation(s)
- W Xie
- Department of Zoology and Genetics, Iowa State University, Ames, Iowa 50011-3260, USA
| | | | | | | | | | | |
Collapse
|
15
|
Gai X, Grigg R, Collard S, Muir JE. Palladium catalysed 3-component cascade synthesis of bis(2-arylallyl) tertiary amines from aryl iodides, allene and primary amines. Chem Commun (Camb) 2001:1712-3. [PMID: 12240278 DOI: 10.1039/b105567b] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A 3-component cascade synthesis of bis(2-arylallyl) tertiary amines from aryl iodide, allene and primary aliphatic amines is described; chiral amines give analogous products with no detectable racemisation; mixtures of two different aryl iodides can be utilised to give the mixed tertiary amines as the sole, or major, product; the reaction is sensitive to stereoelectronic effects which lead to mono(2-arylallyl) secondary amines.
Collapse
Affiliation(s)
- X Gai
- Molecular Innovation, Diversity and Automated Synthesis (MIDAS) Centre, School of Chemistry, Leeds University, Leeds, UK LS2 9JT
| | | | | | | |
Collapse
|
16
|
Taki K, Oogushi K, Hirahara K, Gai X, Nagashima F, Tozuka K. Preferential acetazolamide-induced vasodilation based on vessel size and organ: confirmation of peripheral vasodilation with use of colored microspheres. Angiology 2001; 52:483-8. [PMID: 11515988 DOI: 10.1177/000331970105200707] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
When carbonic anhydrase activity decreases, the regional blood flow (rBF) in organs increases as hypercapnia develops. However, the effects of acetazolamide (AZ)-induced vasodilation have not been estimated with respect to vessel size and organs. The aim of this study was to determine the diameter of the capillaries in various organs that respond to inhibition of carbonic anhydrase activity by AZ. White rabbits were anesthetized with urethane and ketamine and infused with AZ. While the systolic blood pressure (SBP), pH, hemoglobin concentration, and base excess did not change, the partial pressure of arterial oxygen (PaO2) increased significantly and the partial pressure of arterial carbon dioxide (PaCO2) decreased significantly with AZ. The rBF was calculated by using 3 different sizes (15, 25, and 50 microm) of colored microspheres (CM). The rBF measured with 15 microm CM in the brain, kidneys, and liver increased in response to AZ, and the rBF in these organs was different with the different sizes of CM. However, the rBF calculated by using the different sizes of CM in the stomach and abdominal muscle did not change after the administration of AZ. The AZ-induced vasodilation occurred in all sizes of vessels in the liver, in the small and medium-sized vessels in kidneys, and in the larger capillaries in the brain.
Collapse
Affiliation(s)
- K Taki
- Department of Emergency Medicine, Saga Medical College, Japan
| | | | | | | | | | | |
Collapse
|
17
|
Gai X, Grigg R, Collard S, Muir JE. Palladium catalyzed intramolecular nucleophilic addition of allylic species, generated from allene, to aryl aldehydes and ketones. Chem Commun (Camb) 2000. [DOI: 10.1039/b005740l] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
18
|
Gai X, Grigg R, Ramzan MI, Sridharan V, Collard S, Muir JE. Pyrazole and benzothiazole palladacycles: stable and efficient catalysts for carbon–carbon bond formation. Chem Commun (Camb) 2000. [DOI: 10.1039/b005452f] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
19
|
Gai X, Lal S, Xing L, Brendel V, Walbot V. Gene discovery using the maize genome database ZmDB. Nucleic Acids Res 2000; 28:94-6. [PMID: 10592191 PMCID: PMC102455 DOI: 10.1093/nar/28.1.94] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/1999] [Accepted: 10/07/1999] [Indexed: 11/14/2022] Open
Abstract
Zea mays DataBase (ZmDB) is a repository and analysis tool for sequence, expression and phenotype data of the major crop plant maize. The data accessible in ZmDB are mostly generated in a large collaborative project of maize gene discovery, sequencing and phenotypic analysis using a transposon tagging strategy and expressed sequence tag (EST) sequencing. ESTs constitute most of the current content. Database search tools, convenient links to external databases, and novel sequence analysis programs for spliced alignment are provided and together serve as an efficient protocol for gene discovery by sequence inspection. ZmDB can be accessed at http://zmdb. iastate.edu. ZmDB also provides web-based ordering of materials generated in the project, including EST and genomic DNA clones, seeds of mutant plants and microarrays of amplified EST and genomic DNA sequences.
Collapse
Affiliation(s)
- X Gai
- Department of Zoology, Iowa State University, Ames, IA 50011-3260, USA
| | | | | | | | | |
Collapse
|
20
|
Abstract
Many retrotransposons and retroviruses are thought to select integration sites through interactions with specific chromosomal proteins. In yeast, the Ty5 retrotransposon integrates preferentially with regions bound by silent chromatin, namely the telomeres and the HMR and HML mating loci. A Ty5 mutant (M3) was identified with an approximately 20-fold decrease in targeted integration as measured by a plasmid-based targeting assay. Often chromosomal insertions generated by M3, none were located at the telomeres or silent mating loci. A single amino acid change at the boundary of integrase and reverse transcriptase is responsible for the mutant phenotype. We predict that this mutation lies within a targeting domain that mediates Ty5 target choice by interacting with a component of silent chromatin.
Collapse
Affiliation(s)
- X Gai
- Department of Zoology and Genetics, Iowa State University, Ames 50011, USA
| | | |
Collapse
|
21
|
Fu Q, Gai X, Ji Z. [Clinical analysis of surgical treatment for 86 patients with localized small-cell lung cancer]. Zhonghua Zhong Liu Za Zhi 1996; 18:382-4. [PMID: 9387282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
To assess the value of surgical treatment followed by adjuvant chemotherapy for localized small-cell lung cancer (SCLC), the results of treatment in 86 SCLC patients since 1990 were reviewed. Of 86 patients, 19 patients received pneumonectomy, 53 lobectomy, 6 wedge resection and 8 segmental resection. Postoperative pathologic staging revealed 24 in stage I, 36 in stage II, and 26 in stage III. Postoperative adjuvant chemotherapy was given in 78 patients. Until the latest follow-up, 28 patients remained alive and 58 patients died. The 5-year survival rate of the 86 patients was 37%. The survival of patients in stage I was better than that of patients in stage II (P = 0.018) and stage III (P = 0.021), but the survival of patients in stage II was not significantly different from that of patients in stage III (P = 0.234). In summary, surgical treatment followed by chemotherapy improves significantly the survival of patients with localized SCLC. TNM staging is of prognostic importance.
Collapse
Affiliation(s)
- Q Fu
- Department of Surgical Oncology, First Clinical College, Norman Bethune University of Medical Sciences, Changchun
| | | | | |
Collapse
|
22
|
Abstract
In order to examine the role of two inverted CCAAT boxes near the start of transcription of the human thymidine kinase (TK) gene, a series of constructs were prepared in which one or both CCAAT boxes were deleted or mutated. These altered promoters (1.2 kb of 5'-flanking sequence) were used to express a TK minigene containing the first two exons and introns followed by the remainder of the cDNA. RNA blots were prepared from stable cell lines of ts13 cells containing these constructs under three conditions: 1) serum deprived cells, 2) serum stimulated cells, and 3) cells that had been stimulated with serum, but were arrested in the G1 phase of the cell cycle by the temperature sensitive mutation carried by these cells. TK mRNA expression from each construct was suppressed by the temperature sensitive block to cell cycle progression. Measurement of protein expression from the various altered TK promoters indicated that both CCAAT boxes contribute to promoter strength. These experiments also suggested that the two CCAAT boxes were not equivalent and that the distal CCAAT could substitute for the proximal CCAAT, but the converse was not true.
Collapse
Affiliation(s)
- X Mao
- Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
| | | | | | | | | | | | | |
Collapse
|
23
|
Lipson KE, Liang G, Xia L, Gai X, Prystowsky MB, Mao X. Protein that binds to the distal, but not to the proximal, CCAAT of the human thymidine kinase gene promoter. J Cell Biochem 1995; 57:711-23. [PMID: 7615654 DOI: 10.1002/jcb.240570416] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Mobility shift assays were used to examine protein binding to the human TK gene CCAAT boxes. Similar protein binding patterns were observed with probes containing either the proximal or distal CCAAT. However, probes containing both CCAAT boxes in which one of the CCAAT boxes was inactivated by mutation did not demonstrate identical binding patterns. One of the complexes formed with the longer probes was only observed when the distal CCAAT was intact. This species was not formed with probes that only contained an intact proximal CCAAT, and its formation could only be competed by oligonucleotides containing the distal CCAAT motif. This observation reveals the existence of a protein that can bind to the distal, but not to the proximal, CCAAT of the human TK promoter. This protein may account for the previous observation that the two CCAAT motifs are not functionally equivalent. The protein that binds to the distal, but not to the proximal, CCAAT (DTK-CBP) was also present in two human cell lines. Significantly more DTK-CBP was present in nuclear extracts of HepG2 and WI38 cells than in TK-ts13 cells. However, this protein was not observed in three different murine cell lines and one primary culture. Its abundance in some human cell lines suggests it might modulate the expression of human TK mRNA in cells that express this protein.
Collapse
Affiliation(s)
- K E Lipson
- Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway 08854, USA
| | | | | | | | | | | |
Collapse
|